Nuvectis Pharma, Inc. (NVCT) Stock: Dividends & Earnings

Company Overview:

Market Cap: $0

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $5.55 - $29.28

4.7 Year NVCT Performance Metrics:

Total Return (with DRIP): 550% (48.91% CAGR)

Total Return (no DRIP): 550% (48.91% CAGR)

Share Price: 550% (48.91% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $64,985

Total Return $ (with DRIP): $54,985

NVCT Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

NVCT Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Projected Future Returns & Dividends for NVCT

Based on past 4.7-year performance, here are NVCT growth metrics:

Share price CAGR of +48.91%
Dividend CAGR of +0%

Using NVCT CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	NVCT (DRIP)	NVCT - No DRIP
Current Price	$21.12	$21.12
Start Shares	473.48	473.48
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	473.48	473.48
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$21.12	$21.12
Total Dividends	$0	$0
Final Value	$10,000	$10,000

Estimated Future Value + Dividends - NVCT

NOTE: Above numbers are our estimate based on NVCT's Dividend and Price CAGR over past 4.7 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

Nuvectis Pharma, Inc. (NVCT) had its IPO on , and is traded on NASDAQ stock exchange.

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for serious oncology conditions with unmet medical need. The company works on targeted small-molecule therapies designed for genetically defined cancer patient populations, with its current pipeline centered on NXP800 and NXP900. NXP800 is being developed for specific ovarian cancer settings, while NXP900 is designed to inhibit SRC family kinases, including SRC and YES1, in solid tumors. Based in Fort Lee, New Jersey, Nuvectis Pharma operates as a single-segment biotechnology business centered on oncology drug development and clinical research.

NVCT website: https://www.nuvectis.com